Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study

Clinical Rheumatology
Jurgen Sota“Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology)

Abstract

A few studies have reported the safety profile of interleukin (IL)-1 blockers from real life. The aim of this study is to describe anakinra (ANA) and canakinumab (CAN) safety profile in children and adults, based on data from a real-life setting. Demographic, clinical, and therapeutic data from patients treated with ANA and CAN were retrospectively collected and analyzed. Four hundred and seventy five patients were enrolled; ANA and CAN were prescribed in 421 and 105 treatment courses, respectively. During a mean follow-up of 24.39 ± 27.04 months, 89 adverse events (AE) were recorded; 13 (14.61%) were classified as serious AE (sAE). The overall estimated rate of AE and sAE was 8.4 per 100 patients/year. Safety concerns were more frequent among patients aged ≥ 65 years compared with patients < 16 years (p = 0.002). No differences were detected in the frequency of safety concerns between monotherapy and combination therapy with immunosuppressants (p = 0.055), but a significant difference was observed when injection site reactions were excluded from AE (p = 0.01). No differences were identified in relation to gender (p = 0.462), different lines of biologic therapy (p = 0.775), and different dosages (p = 0.70 ANA; p = 0.39 CAN). Th...Continue Reading

References

Dec 31, 1998·Arthritis and Rheumatism·B BresnihanP Musikic
Mar 11, 2009·The Journal of Rheumatology·Ting ZengCheng-De Yang
Sep 2, 2011·Rheumatology International·Christina KaiserBjörn Pilström
Dec 7, 2013·Clinical Rheumatology·Luca CantariniRolando Cimaz
Mar 20, 2014·Dermatology : International Journal for Clinical and Investigative Dermatology·Antonio VitaleLuca Cantarini
Dec 31, 2014·Molecular Medicine·Charles Anthony Dinarello
Mar 12, 2015·Orphanet Journal of Rare Diseases·Linda Rossi-SemeranoUNKNOWN MAIL1 (Maladies Auto-inflammatoires et Anti-IL-1) study Group on behalf of CRI (Club Rhumatisme et Inflammation)
Aug 19, 2015·The American Journal of Cardiology·Sonia JainEric L Matteson
Aug 19, 2015·International Journal of Rheumatic Diseases·Luca CantariniCarlo Selmi
Oct 30, 2016·The Journal of Allergy and Clinical Immunology·Karoline KrauseMarcus Maurer

❮ Previous
Next ❯

Citations

Oct 27, 2018·Expert Review of Clinical Immunology·Gustavo Guimarães Moreira BalbiRoger Abramino Levy
Feb 6, 2020·Current Rheumatology Reports·Priya R SoniMoshe Arditi
May 30, 2019·American Journal of Clinical Dermatology·Kelsey S FloodAlexa B Kimball
Jun 12, 2019·Inflammation and Regeneration·Naoe KanekoJunya Masumoto
Jul 24, 2020·Expert Review of Clinical Immunology·Carla GaggianoClaudia Fabiani
Aug 25, 2019·Italian Journal of Pediatrics·Maria Cristina MaggioGiovanni Corsello
Sep 1, 2020·Expert Opinion on Biological Therapy·Fabiola AtzeniIgnazio Francesco Masala
Sep 20, 2019·Italian Journal of Pediatrics·Maria Cristina MaggioGiovanni Corsello
Feb 26, 2019·Rheumatology International·Alessandra BettiolGiacomo Emmi
Oct 20, 2019·Italian Journal of Pediatrics·Maria Cristina MaggioGiovanni Corsello
Jul 26, 2018·International Journal of Molecular Sciences·Rebekka BentMatthias Bros
Sep 20, 2019·Pediatric Blood & Cancer·Sara R KimMelissa Elder
Jul 4, 2020·International Ophthalmology·Rohan Bir SinghAniruddha Agarwal
Apr 20, 2019·International Journal of Molecular Sciences·Alessandra BettiolFlorenzo Iannone
Jan 17, 2020·Italian Journal of Pediatrics·Maria Cristina Maggio, Giovanni Corsello
Feb 23, 2020·Mediators of Inflammation·Carla GaggianoLuca Cantarini
Apr 16, 2020·Paediatric Drugs·Manel MejbriRolando Cimaz
Sep 5, 2020·Expert Opinion on Drug Safety·Giuseppe LopalcoFlorenzo Iannone
Nov 12, 2020·Journal of Clinical Medicine·Mathilde LeclercqDavid Saadoun
Feb 4, 2021·Cancers·Adrian GottschlichSebastian Kobold
Mar 13, 2021·Frontiers in Pharmacology·Hana MalcovaRudolf Horvath
Mar 24, 2021·Pediatric Rheumatology Online Journal·Elke LainkaHelmut Wittkowski
Apr 16, 2021·International Journal of Immunopathology and Pharmacology·Silvia StefaniaFrancesco Paolo Cantatore
Apr 29, 2021·Inflammation·Barry J LairdIain J Gallagher
May 4, 2021·Frontiers in Pharmacology·Xiaoyan CaiChanghai Ding
May 21, 2021·Current Rheumatology Reports·Fatma Alibaz-Oner, Haner Direskeneli
Aug 17, 2021·Current Opinion in Rheumatology·Rachel L Randell, Mara L Becker
Dec 11, 2019·Journal français d'ophtalmologie·C CouretB Bodaghi
Sep 11, 2021·Rheumatology·Ana Nin-ValenciaCarmen Gómez-Traseira
Oct 9, 2021·Signal Transduction and Targeted Therapy·Kai LiYongsheng Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.